MedTrace Logo

Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France

NCT02835365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2023-01-12

No results posted yet for this study

Summary

Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in neurology to treat spastic contracture. Several clinical studies have suggested its efficacy in the treatment of alcohol-dependence in low, even in case of cirrhosis and high dose. French drug authority has authorized its use in 2012 whereas the l'European Association for the Study of the Liver recommends to perform additional studies on this indication.

The goal of this observational study is to evaluate the use of baclofen for alcohol-dependence in real life care as well its efficacy.

Conditions

  • Alcohol Drinking
  • Cirrhosis
  • Alcohol Withdrawal

Sponsors & Collaborators

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Principal Investigators

  • Camille barrault, MD · CHI Créteil

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2018-08-31
Completion
2018-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02835365 on ClinicalTrials.gov